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BACKGROUND
Survivors of Hodgkin’s lymphoma are at increased risk for treatment-related sub-
sequent malignant neoplasms. The effect of less toxic treatments, introduced in 
the late 1980s, on the long-term risk of a second cancer remains unknown.
METHODS
We enrolled 3905 persons in the Netherlands who had survived for at least 5 years 
after the initiation of treatment for Hodgkin’s lymphoma. Patients had received 
treatment between 1965 and 2000, when they were 15 to 50 years of age. We com-
pared the risk of a second cancer among these patients with the risk that was 
expected on the basis of cancer incidence in the general population. Treatment-
specific risks were compared within the cohort.
RESULTS
With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 
patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence 
interval [CI], 4.3 to 4.9) in the study cohort as compared with the general popula-
tion. The risk was still elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 
2.8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 
40 years was 48.5% (95% CI, 45.4 to 51.5). The cumulative incidence of second 
solid cancers did not differ according to study period (1965–1976, 1977–1988, or 
1989–2000) (P = 0.71 for heterogeneity). Although the risk of breast cancer was 
lower among patients who were treated with supradiaphragmatic-field radiothera-
py not including the axilla than among those who were exposed to mantle-field 
irradiation (hazard ratio, 0.37; 95% CI, 0.19 to 0.72), the risk of breast cancer was 
not lower among patients treated in the 1989–2000 study period than among those 
treated in the two earlier periods. A cumulative procarbazine dose of 4.3 g or more 
per square meter of body-surface area (which has been associated with premature 
menopause) was associated with a significantly lower risk of breast cancer (hazard 
ratio for the comparison with no chemotherapy, 0.57; 95% CI, 0.39 to 0.84) but a 
higher risk of gastrointestinal cancer (hazard ratio, 2.70; 95% CI, 1.69 to 4.30).
CONCLUSIONS
The risk of second solid cancers did not appear to be lower among patients treated 
in the most recent calendar period studied (1989–2000) than among those treated in 
earlier periods. The awareness of an increased risk of second cancer remains crucial 
for survivors of Hodgkin’s lymphoma. (Funded by the Dutch Cancer Society.)
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Since the late 1960s, when combina-tion chemotherapy and high-energy radia-tion therapy were introduced for the treat-
ment of Hodgkin’s lymphoma, survival has 
increased dramatically. Cure has come at a price, 
however, because the treatment of Hodgkin’s 
lymphoma has been shown to increase the risk 
of subsequent malignant neoplasms and other 
late effects considerably.1-22 Although very high 
relative risks have been observed for leukemia 
(especially among patients who were treated 
with alkylating agents) and non-Hodgkin’s lym-
phoma (which was not previously associated 
with a particular type of therapy), second solid 
cancers, the occurrence of which is related pri-
marily to radiation therapy, contribute most to 
the absolute excess risk of a second cancer 
among survivors of Hodgkin’s lymphoma.
At 5 to 10 years after treatment, the relative 
risk of solid cancer is significantly higher among 
survivors of Hodgkin’s lymphoma than in the 
general population, and this higher risk persists 
for at least 25 years.11,19,20 Few studies have inves-
tigated the evolution of a risk of a second solid 
cancer beyond 25 years after treatment.7,11,13,16 
On the basis of increased knowledge of late ef-
fects, the treatment of Hodgkin’s lymphoma has 
changed, with a trend toward the use of smaller 
radiation target volumes, lower radiation doses, 
and more effective, generally less toxic chemo-
therapy schemes.23,24 However, the effect of these 
changes on the risk of a second cancer is still 
unknown.
In this study, we investigated the long-term 
risk of a second cancer and changes in risk over 
time in a large cohort of survivors of Hodgkin’s 
lymphoma in the Netherlands. These patients 
had been treated between 1965 and 2000 and 
had detailed information on primary and relapse 
treatment and complete follow-up for second 
cancers.
Me thods
Study Design and Patients
This study included 3905 persons in the Nether-
lands who had first been treated for Hodgkin’s 
lymphoma between 1965 and 2000, when they 
were between 15 and 50 years of age, and who 
had survived for at least 5 years after receiving 
treatment. Patients were treated at seven aca-
demic centers or in nonacademic hospitals that 
were located within the region of three popula-
tion-based cancer registries. The selection of the 
patients and the methods for data collection 
have been described previously.3,8,10,12,19,22 Detailed 
information regarding radiation fields, chemo-
therapy regimens, and number of cycles, includ-
ing treatment for relapse, was collected from 
medical files.
We used the estimated cumulative dose of 
procarbazine as a measure of the dose of alkyl-
ating chemotherapy, because procarbazine was 
nearly always administered in patients with 
Hodgkin’s lymphoma in a combination chemo-
therapy regimen that included alkylating agents. 
For patients for whom the number of cycles of 
a specific regimen was unknown, the median 
number of cycles administered for either the 
initial treatment or relapse treatment within a 
specific treatment period (1965–1976, 1977–1988, 
or 1989–2000) was imputed.
Information on second cancers, including 
dates of diagnosis, morphologic features, topo-
graphic features, and treatment, was collected 
by a review of medical records, by responses to 
questionnaires sent to general practitioners (the 
response regarding second cancers was 96% com-
plete until 1989),8 and by record linkage with the 
Netherlands Cancer Registry since 1989, when 
the Netherlands Cancer Registry reached nation-
wide coverage. Information on second cancers 
and vital status was complete up to at least 
January 1, 2010.
Statistical Analysis
The time at risk started 5 years after the initia-
tion of treatment and ended at the date of diag-
nosis of the second cancer, the date of death, or 
the data-censoring date. The calculation of the 
expected numbers of solid cancers was based on 
age- sex-, calendar period–, and site-specific 
cancer-incidence rates in the Dutch population, 
multiplied by the corresponding number of 
person-years at risk. From the observed and 
expected numbers of second cancers, we used 
standard methods to compute the standardized 
incidence ratios (SIRs), the absolute excess risk 
per 10,000 person-years, and the corresponding 
95% confidence intervals.25
Tests for homogeneity and trend of SIRs ac-
cording to sex, age, follow-up interval, attained 
age, and treatment (handled as a time-dependent 
variable to account for relapse treatment) were 
A Quick Take 
is available at 
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performed within collapsed person-time Poisson 
regression models. We performed tests for linear 
trends in SIRs by evaluating the likelihood func-
tion of a model with a variable representing the 
follow-up interval or attained age as discrete 
values against the likelihood of a model without 
that variable. Tests for trend with respect to ab-
solute excess risks were performed in additive 
Poisson regression models.26
Basal-cell skin cancers were excluded from all 
the analyses. The myelodysplastic syndrome was 
included only in the analyses of cumulative inci-
dence, because no population reference rates 
were available for this disease. All second can-
cers that were diagnosed within 5 years after the 
start of treatment for Hodgkin’s lymphoma were 
excluded from the analyses; any subsequent sec-
ond cancer was included in the analyses. Pa-
tients in whom multiple second cancers devel-
oped were counted only once in the analysis of 
all second cancers combined; in this analysis, 
the time at risk ended on the date the first sec-
ond cancer was diagnosed. In cancer site–spe-
cific analyses, patients with multiple second 
cancers contributed data regarding a second 
cancer of interest, regardless of whether this 
cancer was preceded by one at another site.
The cumulative incidence of second cancers 
was estimated with death treated as a competing 
risk, and trends over time were evaluated in 
competing-risk models, with adjustment for the 
effects of sex, age, and smoking status when 
appropriate.27 The expected cumulative incidence 
was derived from the expected cancer incidence 
and expected overall mortality in the general 
population, which was estimated with the use of 
the conditional method.28 Factors affecting the 
cumulative incidence of second cancers were as-
sessed with the use of a multivariable Cox re-
gression analysis, with treatment handled as a 
time-dependent variable. All reported P values 
are two-sided; P values of less than 0.05 were 
considered to indicate statistical significance. 
All the analyses were performed with the use of 
Stata statistical software, version 13 (StataCorp).
R esult s
Patients
The cohort included 2207 male and 1698 female 
patients who had survived for at least 5 years 
after the start of treatment for Hodgkin’s lym-
phoma (Table 1; and Table S1 in the Supple-
mentary Appendix, available with the full text 
of this article at NEJM.org). Treatment (includ-
ing treatment for relapse) consisted of radiation 
therapy only in 27.3% of the patients, chemo-
therapy only in 12.1%, and both therapies in 
60.5%. Treatment changed over time; patients 
who were treated in the period from 1989 
through 2000 received smaller radiation target 
volumes,  anthracycline-containing chemotherapy, 
lower doses of alkylating agents, and less fre-
quent infradiaphragmatic irradiation than those 
who were treated in the two earlier periods 
(Table S2 in the Supplementary Appendix).
Characteristic Patients (N = 3905)
no. (%)
Sex
Male 2207 (56.5)
Female 1698 (43.5)
Treatment period
1965–1976 808 (20.7)
1977–1988 1195 (30.6)
1989–2000 1902 (48.7)
Age at first treatment for Hodgkin’s 
lymphoma
15–24 yr 1410 (36.1)
25–34 yr 1326 (34.0)
35–50 yr 1169 (29.9)
Maximum follow-up
5–9 yr 349 (8.9)
10–14 yr 819 (21.0)
15–19 yr 945 (24.2)
20–24 yr 716 (18.3)
25–29 yr 464 (11.9)
30–34 yr 330 (8.5)
35–39 yr 180 (4.6)
≥40 yr 102 (2.6)
Treatment category*
Radiation therapy only 1068 (27.3)
Chemotherapy only 473 (12.1)
Radiation therapy and chemo-
therapy
2364 (60.5)
*  Data include treatment for recurrence. Percentages may 
not total 100 because of rounding.
Table 1. Characteristics of the Patients.
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The median age of the patients at the start 
of treatment was 28.6 years, and the median 
follow-up was 19.1 years (range 5.0 to 47.2), 
with 27.5% of patients being followed for at least 
25 years. The median age of the patients at the 
end of follow-up was 50.4 years.
Observed Risk of Second Cancer as Compared 
with the General Population
During follow-up, 1055 second cancers were diag-
nosed in 908 patients; a third cancer developed 
in 130 patients, and a fourth developed in 17. 
The risk of a second cancer among patients who 
had been treated for Hodgkin’s lymphoma was 
higher than the incidence of cancer in the gen-
eral population (SIR, 4.6; 95% confidence inter-
val [CI], 4.3 to 4.9), which resulted in 121.8 ex-
cess cancers per 10,000 person-years (Table 2).
SIRs were significantly higher in the study 
cohort than in the general population for can-
cers at all sites at which at least 10 second can-
cers were observed, with the exception of pros-
tate cancer. Risks that were more than 10 times 
as high as those observed in the general popu-
lation were seen for thyroid cancer, soft-tissue 
sarcoma, mesothelioma, and non-Hodgkin’s 
lymphoma, whereas SIRs were 5 to 10 times as 
high for esophageal, stomach, pancreatic, and 
lung cancer as well as leukemia. The signifi-
cantly higher relative risks of thyroid cancer, 
mesothelioma, and soft-tissue sarcoma were as-
sociated with low absolute risks (30-year cumu-
lative incidence, 0.8%, 0.6%, and 0.7%, respec-
tively), owing to low background risks in the 
population.
Breast cancer contributed most to the overall 
absolute excess risk (24.9 cases of breast cancer 
per 10,000 person-years among men and women), 
representing 20.4% of the excess risk of any 
second cancer (121.8 cases per 10,000 person-
years) in the cohort; the absolute excess risk of 
breast cancer among women was 54.3 cases per 
10,000 person-years, representing 40.5% of the 
excess risk of any second cancer (134.0 cases per 
10,000 person-years) among women in the co-
hort. Lung cancer was the next most common 
(absolute excess risk, 24.6 cases per 10,000 person-
years, representing 20.2% of the excess risk in 
the cohort), followed by gastrointestinal tract 
cancer (19.7% of the excess risk) and non-Hodg-
kin’s lymphoma (13.1% of the excess risk). The 
absolute excess risk of leukemia accounted for 
only 5.0% of the absolute excess risk of any sec-
ond cancer.
Relative and Absolute Excess Risk According 
to Sex, Age, and Follow-up
The SIR for any second cancer remained high for 
at least 35 years after the start of treatment for 
Hodgkin’s lymphoma (SIR for ≥35 years, 3.9; 
95% CI, 2.8 to 5.4) (Fig. 1A), whereas the ab-
solute excess risk increased steadily over time 
(P<0.001 for trend) (Fig. 1B). After 35 years or 
more of follow-up, survivors of Hodgkin’s lym-
phoma had 364 excess cancers per 10,000 person-
years. SIRs did not differ appreciably between 
men and women.
The SIRs for second solid cancers decreased 
with increasing age at the time of diagnosis of 
Hodgkin’s lymphoma (P<0.001 for trend) (Table 
S3 in the Supplementary Appendix), rose over the 
first 15 years of follow-up, and remained stable 
thereafter. The absolute excess risk of solid can-
cers increased with attained age in the cohort 
(P<0.001 for trend, regardless of age at start of 
treatment), but SIRs decreased with older at-
tained ages (P<0.001 for trend). Survivors of 
Hodgkin’s lymphoma who were in their 60s had 
1.7 excess cancers per 100 person-years and 
those in their 70s had 3.1 excess cancers per 
100 person-years, on top of a background inci-
dence of 1.3 and 2.1 cancers per 100 person-years, 
respectively.
The SIRs for lung cancer did not decrease 
with increasing age at the time of treatment for 
Hodgkin’s lymphoma as strongly as they did for 
breast cancer and gastrointestinal tract cancer. 
As compared with the incidence in the general 
population, the SIR for lung cancer was 5.2 
among patients who had been treated for Hodg-
kin’s lymphoma when they were 35 to 50 years 
of age. In addition, higher SIRs became apparent 
earlier (5 to 9 years after the first treatment) for 
lung cancer than for breast cancer and gastroin-
testinal tract cancer.
Cumulative Incidence According to 
Treatment Period
At 30 years after the start of treatment for Hodg-
kin’s lymphoma, the cumulative incidence of any 
second cancer, including the myelodysplastic 
syndrome, was 33.2% (95% CI, 31.1 to 35.3%), as 
compared with the expected cumulative inci-
dence of cancer of 9.6% in the general population. 
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Second Cancer or Cancer Site
ICD 
Code
No. of 
Patients
Standardized 
Incidence Ratio 
(95% CI)
Absolute 
Excess Risk
30-Yr Cumulative 
Incidence 
(95% CI)
no./10,000 person-yr 
(95% CI)
Any cancer, excluding MDS† — 884 4.6 (4.3 to 4.9) 121.8 (111.8 to 132.4) 32.5 (30.4 to 34.6)
Any solid cancer C00–C80 757 4.2 (3.9 to 4.5) 100.5 (91.3 to 110.2) 28.5 (26.4 to 30.5)
Lip, oral cavity, or pharynx C00–C14 20 3.2 (2.0 to 4.9) 2.3 (1.0 to 4.1) 0.5 (0.3 to 0.9)
Gastrointestinal tract C15–C26 184 4.6 (3.9 to 5.3) 24.0 (19.7 to 28.7) 7.0 (5.9 to 8.3)
Esophagus C15 38 9.5 (6.7 to 13.1) 5.6 (3.8 to 8.0) 1.5 (1.0 to 2.1)
Stomach C16 39 7.4 (5.3 to 10.1) 5.6 (3.7 to 8.0) 1.6 (1.1 to 2.3)
Colon C18 42 2.9 (2.1 to 3.9) 4.6 (2.6 to 7.0) 1.5 (1.0 to 2.1)
Rectum or rectosigmoid junction C19–C20 25 2.6 (1.7 to 3.9) 2.6 (1.1 to 4.5) 1.0 (0.6 to 1.5)
Pancreas C25 23 5.7 (3.6 to 8.5) 3.1 (1.7 to 5.0) 1.0 (0.6 to 1.6)
Lower respiratory system C33, C34, 
and C45
193 6.7 (5.8 to 7.8) 27.3 (22.9 to 32.1) 7.1 (6.0 to 8.3)
Lung or bronchus C34 176 6.4 (5.5 to 7.4) 24.6 (20.5 to 29.3) 6.4 (5.4 to 7.6)
Mesothelioma C45 17 15.1 (8.8 to 24.2) 2.6 (1.5 to 4.3) 0.6 (0.3 to 1.1)
Skin
Melanoma C43 34 2.8 (1.9 to 3.9) 3.6 (1.9 to 5.9) 1.1 (0.7 to 1.5)
Nonmelanoma C44 26 3.4 (2.2 to 5.0) 3.1 (1.6 to 5.1) 0.7 (0.4 to 1.2)
Soft-tissue sarcoma C47–C49 22 12.0 (7.5 to 18.2) 3.3 (2.0 to 5.2) 0.7 (0.4 to 1.1)
Female breast‡ C50 183 4.7 (4.0 to 5.4) 54.3 (44.7 to 65.0) 16.6 (14.1 to 19.2)
Female genital organ
Any C51–C58 34 2.8 (1.9 to 3.9) 3.6 (1.9 to 5.9) 2.9 (2.0 to 4.2)
Corpus uteri C54 16 3.6 (2.1 to 5.8) 1.9 (0.8 to 3.6) 1.6 (0.9 to 2.6)
Male genital organ
Any C60–C63 22 1.1 (0.7 to 1.7) 0.3 (−1.0 to 2.2) 1.8 (1.1 to 2.8)
Prostate C61 18 1.0 (0.6 to 1.7) 0.1 (−1.1 to 1.9) 1.4 (0.8 to 2.4)
Urinary tract C64–C68 39 3.5 (2.5 to 4.7) 4.6 (2.7 to 7.0) 1.3 (0.9 to 2.0)
Kidney C64 12 2.3 (1.2 to 4.1) 1.1 (0.2 to 2.6) 0.4 (0.2 to 0.8)
Urinary bladder C67 22 4.1 (2.6 to 6.2) 2.8 (1.4 to 4.6) 0.6 (0.3 to 1.1)
Thyroid gland C73 23 14.0 (8.9 to 21.0) 3.5 (2.1 to 5.5) 0.8 (0.5 to 1.2)
Primary site unknown or ill defined C76–C80 29 4.9 (3.3 to 7.0) 3.8 (2.2 to 5.9) 1.3 (0.8 to 1.9)
Blood, bone marrow, or lymphatic 
system
C82–C96 147 10.4 (8.8 to 12.2) 22.2 (18.4 to 26.5) 5.0 (4.1 to 6.0)
Non-Hodgkin’s lymphoma C82–88 104 13.4 (10.9 to 16.2) 16.0 (12.9 to 19.7) 3.7 (3.0 to 4.6)
Leukemia C91–96 41 9.5 (6.8 to 12.9) 6.1 (4.2 to 8.5) 1.3 (0.9 to 1.7)
*  The standardized incidence ratios and absolute excess risks are for the comparison of the incidence of second cancer observed in the study 
cohort with the expected incidence of that cancer in the general population. The listed cancers are those of which at least 10 cases were ob-
served in the cohort. ICD denotes International Classification of Diseases, 10th Revision, and MDS the myelodysplastic syndrome.
†  Data include the first subsequent malignant neoplasm after Hodgkin’s lymphoma. Besides the specific sites noted in the table, we observed 
the following cancers: three cancers of the tongue (C02), six oral cavity cancers (C03–C06), seven salivary gland cancers (C07–C08), two oro-
pharynx cancers (C01, C09–C10), two nasopharyngeal cancers (C11), two hypopharyngeal cancers (C12–C13), four small intestine cancers (C17), 
six anal cancers (C21), eight liver cancers (C22), one gallbladder cancer (C23), four extrahepatic biliary tract cancers (C24), two other or ill-
defined gastrointestinal cancers (C26), three larynx cancers (C32), one intrathoracic (mediastinal) cancer (C38), five bone cancers (C40–C41), 
four male breast cancers (C50), two vulva cancers (C51), eight cervical cancers (C53), eight ovarian cancers (C56), one placenta cancer (C58), 
three penis cancers (C60), one testis cancer (C62), one renal pelvis cancer (C65), one ureter cancer (C66), three unspecified urinary system cancers 
(C68), four meningiomas (C70), six brain tumors (C71), seven other central nervous system tumors (C72), and three multiple myelomas (C90).
‡  Only women were included in the denominator. For breast cancer, women accumulated 26,517.1 person-years, in which 39.0 breast cancers 
were expected (rounded data). An additional 30 women received a diagnosis of an in situ breast carcinoma.
Table 2. Standardized Incidence Ratios, Absolute Excess Risks, and 30-Year Cumulative Incidences of Selected Subsequent Malignant Neoplasms.*
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At 40 years, the cumulative incidence was 48.5% 
(95% CI, 45.4 to 51.5), as compared with the 
expected cumulative incidence of 19.0% in the 
general population. At 30 years, the cumulative 
incidence of breast cancer among women in the 
study cohort was 16.6% (95% CI, 14.1 to 19.2), 
and the cumulative incidence of lung cancer was 
8.3% (95% CI, 6.7 to 10.0) among men and 4.1% 
(95% CI, 2.9 to 5.6) among women.
Figure 2, and Figure S1 in the Supplementary 
Appendix, show the cumulative incidence of se-
lected second cancers according to the period of 
diagnosis of Hodgkin’s lymphoma. In a multi-
variable analysis, with adjustment for sex, age, 
and smoking status, the cumulative incidence of 
any second cancer was lower among patients 
treated in the period from 1989 through 2000 
than among those treated in the period from 
1965 through 1976 (subdistribution hazard ratio, 
0.79; 95% CI, 0.65 to 0.95; P = 0.02 for trend) 
(Fig. 2A, and Table S4 in the Supplementary Ap-
pendix). The cumulative incidence of second 
solid cancers did not differ significantly among 
the treatment periods (P = 0.71 for heterogene-
ity), nor did the cumulative incidence of breast 
cancer (P = 0.17 for heterogeneity) or gastrointes-
tinal cancer (P = 0.22 for heterogeneity) (Fig. 2B 
and 2D, and Fig. S1B in the Supplementary Ap-
pendix).
The trend in the cumulative incidence of lung 
cancer according to period of treatment differed 
between men and women (P = 0.02 for interac-
tion). Although the cumulative incidence was 
lower among men treated in the period from 
1989 through 2000 than among those treated in 
the two earlier periods (P = 0.001 for trend) (Fig. 
S1A in the Supplementary Appendix), the inci-
dence among women increased over time 
(P = 0.14 for trend) (Fig. 2C).
The cumulative incidence of non-Hodgkin’s 
lymphoma more than halved between the period 
of 1965 through 1976 and the period of 1989 
through 2000 (P = 0.003 for trend, with adjust-
ment for sex and age) (Fig. S1C in the Supple-
mentary Appendix). Similarly, the cumulative 
incidence of leukemia (and the myelodysplastic 
syndrome) was much lower among patients who 
were treated in the period from 1989 through 
2000 than among those who were treated in the 
period from 1965 through 1976 (subdistribution 
hazard ratio, 0.24; 95% CI, 0.12 to 0.49; P<0.001 
for trend) (Fig. S1D in the Supplementary Ap-
pendix).
Associations of Treatment with Standardized 
Incidence Ratios
As compared with the incidence of cancer in the 
general population, the SIR for supradiaphrag-
matic second solid cancers was 6.3 (95% CI, 5.7 
to 6.9) among patients treated with supradia-
phragmatic irradiation. Patients who were not 
treated with supradiaphragmatic irradiation also 
Figure 1. Standardized Incidence Ratios and Absolute Excess Risks of Any 
Subsequent Malignant Neoplasm after Treatment for Hodgkin’s Lymphoma, 
According to Follow-up Interval.
The standardized incidence ratio is a comparison of the incidence of second 
cancer observed in the study cohort with the expected incidence in the 
general population. Vertical lines indicate 95% confidence intervals.
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had a higher risk of second solid cancers above 
the diaphragm (SIR, 2.1; 95% CI, 1.4 to 2.9; 
P<0.001 for heterogeneity) (Table S5 in the Sup-
plementary Appendix).
All but five of the patients in whom breast 
cancer developed had received supradiaphrag-
matic radiation therapy (SIR, 5.4, vs. 1.0 among 
patients treated without supradiaphragmatic ra-
diation therapy; P<0.001 for heterogeneity). The 
risk of breast cancer decreased with increasing 
procarbazine dose among patients treated with 
supradiaphragmatic irradiation; the SIRs were 
3.8 among patients who received procarbazine-
containing chemotherapy and 6.8 among those 
who did not receive such chemotherapy (P = 0.001 
for heterogeneity).
The SIR for lung cancer was 7.7 (95% CI, 6.5 to 
9.0) among patients treated with supradiaphrag-
matic irradiation. However, it was also elevated 
among patients treated with procarbazine-con-
taining chemotherapy without supradiaphrag-
matic irradiation (SIR, 3.2; 95% CI, 1.8 to 5.3).
Of the 230 patients in whom a second solid 
cancer developed below the diaphragm, 146 
(63.5%) had received infradiaphragmatic radia-
tion therapy (SIR, 4.6; 95% CI, 3.9 to 5.4). The 
SIR was 1.7 (95% CI, 1.3 to 2.1) among patients 
who had been treated without infradiaphrag-
Figure 2. Cumulative Incidence of Subsequent Malignant Neoplasms, According to Treatment Period, with Death as a Competing Risk.
Solid lines represent the observed incidence, and dashed lines the expected incidence in the general population. The insets show the 
same data on enlarged y axes.
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matic radiation therapy (P<0.001 for heterogene-
ity). SIRs were higher with increasing procarba-
zine dose (P<0.001 for trend), regardless of 
treatment with infradiaphragmatic irradiation. 
The risk of gastrointestinal cancer was highest 
among patients treated with infradiaphragmatic 
irradiation and procarbazine-containing chemo-
therapy (SIR, 8.6; 95% CI, 6.4 to 11.4) (Table S5 
in the Supplementary Appendix).
Associations of Treatment with Risk  
of Second Cancer in the Cohort
In the comparison of treatments within the co-
hort, multivariable analysis showed that patients 
who received supradiaphragmatic field radio-
therapy not including the axilla had a much 
lower risk of a second solid cancer than patients 
who received complete mantle-field radiotherapy 
(hazard ratio, 0.63; 95% CI, 0.49 to 0.83) (Ta-
ble 3). This finding is due largely to the signifi-
cantly lower risk of breast cancer among pa-
tients who received supradiaphragmatic field 
radiotherapy not including the axilla than among 
those who received complete mantle-field radio-
therapy (hazard ratio, 0.37; 95% CI, 0.19 to 0.72). 
The risk of breast cancer was also lower with 
higher cumulative procarbazine doses (hazard 
ratio for a cumulative procarbazine dose of ≥4.3 g 
per square meter of body-surface area vs. no 
chemotherapy, 0.57; 95% CI, 0.39 to 0.84; 
P = 0.002 for trend). Patients who were treated 
with mantle-field irradiation had a risk of lung 
cancer that was similar to the risk among those 
who were treated with less-extensive supradia-
phragmatic field irradiation (hazard ratio, 1.04; 
P = 0.84).
The risk associated with smoking appeared to 
multiply the elevated lung-cancer risk associated 
with supradiaphragmatic irradiation. As com-
pared with nonsmokers who did not receive supra-
diaphragmatic radiotherapy, the largest risk was 
observed among persons who were former or 
current smokers and who received supradia-
phragmatic radiotherapy (hazard ratio, 14.38; 
95% CI, 6.99 to 29.58). The hazard ratio among 
nonsmokers who received supradiaphragmatic 
radiotherapy was 2.96 (95% CI, 1.76 to 4.97), and 
the hazard ratio among former or current smok-
ers who did not receive supradiaphragmatic radio-
therapy was 4.86 (95% CI, 2.97 to 7.95).
The risk of stomach, pancreatic, or colorectal 
cancer was higher after infradiaphragmatic radio-
therapy (P<0.001 for heterogeneity); the risks 
were also higher with procarbazine-containing 
chemotherapy than with no chemotherapy (haz-
ard ratio for procarbazine dose ≥4.3 g per square 
meter, 2.70; 95% CI, 1.69 to 4.30). Patients who 
had undergone splenectomy had a higher risk of 
non-Hodgkin’s lymphoma than did those who 
had not undergone splenectomy (hazard ratio, 
1.76; 95% CI, 1.09 to 2.84). Also, mantle-field 
or supradiaphragmatic irradiation including the 
axilla, as compared with no radiotherapy, and 
a cumulative dose of procarbazine that was 
greater than 8.4 g per square meter, as com-
pared with no chemotherapy, were associated 
with a higher risk of non-Hodgkin’s lymphoma, 
although the absolute risk was small. The 30-
year cumulative incidence of non-Hodgkin’s lym-
phoma was 4.8% (95% CI, 3.8 to 6.0) among 
patients who received mantle-field radiotherapy 
and a cumulative procarbazine dose of more 
than 8.4 g per square meter, as compared with 
2.0% (95% CI, 1.0 to 3.6) among patients who 
did not receive mantle-field radiotherapy and 
high-dose procarbazine. Results did not differ 
substantially according to the number of cycles 
with alkylating chemotherapy (Table S6 in the 
Supplementary Appendix).
Discussion
This large cohort study with long-term and com-
plete follow-up showed that the risk of second 
solid cancers did not change appreciably among 
patients with Hodgkin’s lymphoma who were 
treated during the 1990s (study period 1989–
2000), as compared with those who were treated 
during earlier decades. However, the risk of he-
matopoietic second cancers has clearly decreased 
among 5-year survivors who were treated in the 
most recent study period, which correlates with 
the declining use of alkylating agent–based che-
motherapy. During follow-up, the SIR for second 
solid cancers remained remarkably stable, result-
ing in strongly increasing excess rates of a sec-
ond cancer when survivors of Hodgkin’s lym-
phoma reached ages at which background cancer 
rates were substantial. Even 40 years after treat-
ment, survivors of Hodgkin’s lymphoma were at 
increased risk for second cancers, with the cu-
mulative incidence reaching 48.5%.
Breast cancer accounted for more than 40% 
of the excess risk of a second cancer among 
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women in our cohort. As compared with mantle-
field irradiation, radiation therapy with less-
extensive supradiaphragmatic fields was associ-
ated with a substantially lower risk of breast 
cancer, which confirms our previous results, 
which were based on smaller numbers.9 None-
theless, although a larger proportion of more 
recently treated female survivors of Hodgkin’s 
lymphoma had received less-extensive supradia-
phragmatic irradiation, there was little evidence 
that these women had a lower risk of breast 
cancer than those who were treated in the two 
earlier periods.
The interpretation of the surprising absence 
of a decline in the rate of second breast cancers 
with less radiation exposure is complicated. It 
was expected that lower volumes of supradia-
phragmatic radiation therapy would result in 
lower rates of breast cancer. It is possible, how-
ever, that the changes in radiation-therapy poli-
cies were not yet applied widely enough to re-
duce the risk of breast cancer. It is also possible 
that the absence of a decrease in the incidence 
of breast cancer is due in part to the earlier de-
tection of breast cancer in more recently treated 
women because of higher rates and earlier starts 
of screening, as compared with the earlier treat-
ment cohorts.29 We evaluated methods of breast-
cancer detection at four participating hospitals. 
Before 2001, a total of 29.7% of the breast cancers 
(11 of 37 cases) were detected by means of breast-
cancer screening (routine palpation, mammog-
raphy, or magnetic resonance imaging); the rate 
is 60.8% (48 of 79) since 2001.
Furthermore, our data indicate that the intro-
duction of less-gonadotoxic chemotherapy may 
have influenced the risk of breast cancer. In the 
two earlier periods, high doses of alkylating 
agents were frequently used, often causing pre-
mature menopause, which has been associated 
with a lower risk of radiation-associated breast 
cancer, as compared with lower doses of alkylat-
ing agents (≤4.2 g of procarbazine per square 
meter) or no chemotherapy.5,6,9,14 The survival rate 
after the diagnosis of breast cancer appeared to 
be similar among patients with Hodgkin’s lym-
phoma who received a diagnosis of breast cancer 
before 2001 and those who received the diagno-
sis since 2001 (overall survival at 5 years, 80.0% 
and 77.5%, respectively).
Although male survivors of Hodgkin’s lym-
phoma who were treated in the period from 
1989 through 2000 had a lower risk of lung 
cancer than those who were treated in the period 
from 1965 through 1976, the risk of lung cancer 
increased over time among female survivors — 
a finding that mirrors trends in smoking rates 
and lung-cancer incidence over the past decades 
in the general population. Supradiaphragmatic 
radiotherapy was associated with a higher risk of 
lung cancer than the risk among patients who 
were not treated with supradiaphragmatic radio-
therapy, and the risk did not differ significantly 
between patients treated with mantle-field irra-
diation and those treated with irradiation of 
other supradiaphragmatic fields. Apparently, the 
latter, less-extensive radiation fields are still asso-
ciated with considerable radiation exposure of 
the lungs.
Previously, a higher risk of lung cancer was 
found among patients treated with alkylating 
chemotherapy than among those who had not 
received alkylating chemotherapy, with higher 
risks observed with increasing number of chemo-
therapy cycles.17,18 Our data do not support an 
association of lung-cancer risk with a higher 
dose of procarbazine-containing chemotherapy 
nor with an increasing number of cycles of alkyl-
ating chemotherapy. Although patients who re-
ceived procarbazine-containing chemotherapy 
and did not receive supradiaphragmatic radio-
therapy had a risk of lung cancer that was 3.2 
times as high as that in the general population, 
chemotherapy did not appear to affect lung-
cancer risk in the multivariable analysis — a 
finding that is consistent with the results of a 
previous case–control study conducted by our 
group.21
The cumulative incidence of gastrointestinal 
second cancers (stomach, pancreatic, or colorec-
tal cancers) did not change appreciably over 
time. This finding is remarkable because consid-
erably fewer patients who were treated in the 
period from 1989 through 2000 than who were 
treated in the two earlier periods received infra-
diaphragmatic radiotherapy. Infradiaphragmatic 
radiotherapy was significantly associated with 
the risk of gastrointestinal second cancer in our 
analyses and in previous studies.1,4,10 Procarba-
zine-containing chemotherapy was associated 
with an overall risk of gastrointestinal second 
cancer that was 2.5 times as high as the risk 
without chemotherapy, without a clear effect of 
number of cycles. This finding confirms results 
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that showed a higher risk of stomach cancer 
after procarbazine, as compared with no procar-
bazine, with a strong interaction with radiation 
dose.4,10 A considerably larger proportion of pa-
tients with Hodgkin’s lymphoma who were treat-
ed in the period from 1989 through 2000 than 
who were treated in the earlier calendar periods 
received chemotherapy.
Several previous studies have shown a higher 
risk of non-Hodgkin’s lymphoma among survi-
vors of Hodgkin’s lymphoma than in the general 
population, the cause of which remains un-
clear.7,15,16,19,20 Besides the possibility that the 
primary Hodgkin’s lymphoma was misclassified 
(i.e., was actually non-Hodgkin’s lymphoma), 
immunosuppression in survivors has been sug-
gested as a possible explanation for this higher 
risk of non-Hodgkin’s lymphoma.30,31 Our find-
ing of a higher risk of non-Hodgkin’s lymphoma 
associated with splenectomy, as compared with 
no splenectomy, seems to support this hypothe-
sis. Fortunately, splenectomy is now rarely a 
component of the care of patients with Hodg-
kin’s lymphoma. However, mantle-field irradia-
tion and high cumulative doses of procarbazine 
were also associated with a high risk of non-
Hodgkin’s lymphoma.
The strengths of our study include complete, 
long-term follow-up and the availability of de-
tailed treatment data. We acknowledge that we 
present the results of many tests of statistical 
significance, and we therefore caution against 
overinterpretation of our findings, especially when 
they are based on P values of more than 0.001.
In conclusion, even 40 years after treatment 
for Hodgkin’s lymphoma, survivors remain at 
increased risk for second cancers. The risk of 
solid cancer after treatment for Hodgkin’s lym-
phoma was not lower among more recently 
treated patients than among those who were 
treated in earlier time periods, despite changes 
in treatment. Our results suggest that reducing 
the incidence of second cancers can best be 
achieved by a substantial reduction in the radia-
tion exposure of healthy organs and tissues and 
by avoidance of high-dose procarbazine. Current 
common practice in radiation oncology, includ-
ing involved-node or involved-site radiotherapy, 
three-dimensional conformal radiation treatment 
planning (in which multiple beams of radiation 
are shaped to match the target volume), and ra-
diation doses of less than 36 Gy, was not applied 
in our study population. It is hoped that these 
changes may reduce the risk of solid cancer 
among patients treated after 2000.23,32 At present, 
we are unable to conclude that changes made 
before 2000 had a measurable effect on the risk 
of a second solid cancer.
For patients with newly diagnosed Hodgkin’s 
lymphoma, the risks of both radiation-related 
and chemotherapy-related late toxic effects must 
be carefully balanced against the risk of failing 
to control the primary disease. Awareness of the 
increased risk of subsequent malignant neo-
plasms remains of great importance for survivors 
of Hodgkin’s lymphoma and for their physicians.
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